MAVYRET: FOR CHRONIC HCV
TREAT ALL GENOTYPES
IN AS FEW AS 8 WEEKS
THE ONLY 8-WEEK† PANGENOTYPIC REGIMEN FOR
GT 1–6 TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1
*Cure = sustained virologic response (SVR12); HCV RNA <LLOQ at 12 weeks after the end of treatment.
†Excludes liver or kidney transplant recipients.
‡IQVIA data includes NPA week ending 1/19/18-8/10/18; WSP and LRx week ending 1/19/18-8/3/18.4
HIGH CURE* RATES IN 8 WEEKS†
demonstrated in clinical trials in treatment-naïve, non-cirrhotic patients
OVERALL DISCONTINUATION RATE DUE TO ADVERSE REACTIONS
Most common adverse
prevalence) were headache and fatigue